# Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D

> **NCT03841526** · PHASE2 · COMPLETED · sponsor: **Xeris Pharmaceuticals** · enrollment: 48 (actual)

## Conditions studied

- Hypoglycemia

## Interventions

- **DRUG:** Glucagon RTU Injection With Insulin Pump Reduction
- **OTHER:** Vehicle for Glucagon RTU Injection With Insulin Pump Reduction
- **DRUG:** Glugaon RTU Injection Without Insulin Pump Reduction

## Key facts

- **NCT ID:** NCT03841526
- **Lead sponsor:** Xeris Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-22
- **Primary completion:** 2020-04-02
- **Final completion:** 2020-04-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03841526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03841526, "Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03841526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*